PE20110775A1 - Composicion para dirigirse a las celulas dendriticas - Google Patents

Composicion para dirigirse a las celulas dendriticas

Info

Publication number
PE20110775A1
PE20110775A1 PE2011000926A PE2011000926A PE20110775A1 PE 20110775 A1 PE20110775 A1 PE 20110775A1 PE 2011000926 A PE2011000926 A PE 2011000926A PE 2011000926 A PE2011000926 A PE 2011000926A PE 20110775 A1 PE20110775 A1 PE 20110775A1
Authority
PE
Peru
Prior art keywords
composition
antigens
melanoma
refers
address
Prior art date
Application number
PE2011000926A
Other languages
English (en)
Inventor
Joseph Altin
Ines Atmosukarto
Wildt Rudolf Maria De
Christopher Parish
Jason Price
Original Assignee
Domantis Ltd
Lipotek Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd, Lipotek Pty Ltd filed Critical Domantis Ltd
Publication of PE20110775A1 publication Critical patent/PE20110775A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA EN FORMA DE VACUNA QUE COMPRENDE: A) UNO O MAS ANTIGENOS TUMORALES ASOCIADOS CON MEMBRANA TALES COMO ANTIGENOS DE DIFERENCIACION DE MELANOMA DE TIROSINASA, gp100 Y MART-1, Y LOS ANTIGENOS DE CANCER DE TESTICULOS MAGE-A3, MAGE A-10, BAGE, GACE Y XAGE; B) UN SOLO DOMINIO VARIABLE DE INMUNOGLOBULINA ANTI-DC-SIGN TAL COMO EL FRAGMENTO DE dAb DE LA CADENA PESADA QUE COMPRENDE LA SEQ ID Nº: 1 O LA SEQ ID Nº: 3; C) UN VEHICULO TAL COMO UN LIPOSOMA QUE COMPRENDE EL LIPIDO QUELANTE DE 3(ACIDO NITRILO-TRIACETICO)-DITETRADECIL-AMINA (3NTA-DTDA), SULFATO DE NIQUEL (NiSO4), LIPIDO DE a-PALMITOIL-B-OLEOIL-FOSFATIDIL-COLINA (POPC); Y D) UN FACTOR INMUNOMODULADOR TAL COMO LA CITOQUINA DE INTERFERON GAMMA (IFN-GAMMA). TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION DE DICHA COMPOSICION LA CUAL ES UTIL EN EL TRATAMIENTO DE MELANOMA
PE2011000926A 2008-10-21 2009-10-19 Composicion para dirigirse a las celulas dendriticas PE20110775A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10709508P 2008-10-21 2008-10-21

Publications (1)

Publication Number Publication Date
PE20110775A1 true PE20110775A1 (es) 2011-10-21

Family

ID=41600775

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000926A PE20110775A1 (es) 2008-10-21 2009-10-19 Composicion para dirigirse a las celulas dendriticas

Country Status (18)

Country Link
US (2) US8779107B2 (es)
EP (1) EP2355797A1 (es)
JP (1) JP2012506371A (es)
KR (1) KR20110101134A (es)
CN (1) CN102281867A (es)
AU (1) AU2009306425B2 (es)
BR (1) BRPI0919670A2 (es)
CA (1) CA2740857A1 (es)
CL (1) CL2011000911A1 (es)
CO (1) CO6361908A2 (es)
EA (1) EA201100485A1 (es)
IL (1) IL212147A0 (es)
MA (1) MA32815B1 (es)
MX (1) MX2011004245A (es)
NZ (1) NZ592084A (es)
PE (1) PE20110775A1 (es)
WO (1) WO2010046338A1 (es)
ZA (1) ZA201102764B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120132183A (ko) * 2011-05-27 2012-12-05 포항공과대학교 산학협력단 종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신
EP3873532A1 (en) 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody drug conjugates
EP3976071A1 (en) * 2019-05-29 2022-04-06 Université de Tours Toxoplasma platform for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1639011T3 (pl) * 2003-06-30 2009-05-29 Domantis Ltd Pegilowane przeciwciała jednodomenowe (dAb)
WO2005018610A1 (en) * 2003-08-21 2005-03-03 Lipotek Pty Ltd In vivo targeting of dendritic cells
EA201100488A1 (ru) * 2008-10-21 2011-12-30 Домантис Лимитед Лиганды, которые обладают специфичностью связывания в отношении dc-sign

Also Published As

Publication number Publication date
IL212147A0 (en) 2011-06-30
US20110212168A1 (en) 2011-09-01
CN102281867A (zh) 2011-12-14
JP2012506371A (ja) 2012-03-15
WO2010046338A1 (en) 2010-04-29
BRPI0919670A2 (pt) 2019-09-24
ZA201102764B (en) 2012-09-26
AU2009306425A1 (en) 2010-04-29
EA201100485A1 (ru) 2011-12-30
AU2009306425B2 (en) 2013-09-12
MX2011004245A (es) 2011-09-06
NZ592084A (en) 2013-01-25
CA2740857A1 (en) 2010-04-29
CO6361908A2 (es) 2012-01-20
US8779107B2 (en) 2014-07-15
KR20110101134A (ko) 2011-09-15
US20140341971A1 (en) 2014-11-20
EP2355797A1 (en) 2011-08-17
MA32815B1 (fr) 2011-11-01
CL2011000911A1 (es) 2012-02-03

Similar Documents

Publication Publication Date Title
AR127117A2 (es) Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores
CY1125057T1 (el) Anti-cd277 αντισωματα και χρησεις αυτων
CL2020001989A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia linfocítica crónica (llc) y otros tipos de cáncer. (divisional solicitud 201801532)
MX2015001871A (es) Celulas asesinas naturales y usos de las mismas.
BR112016009402A2 (pt) Peptídeo, linfócitos t citotóxicos (ltc) ativados, método para sua produção, anticorpo, receptor de células t, ácido nucleico, célula hospedeira, uso dos mesmos, kit, método para produzir uma vacina anticâncer personalizada para um paciente individual
MX347515B (es) Agentes que se unen al receptor encrespado y usos de los mismos.
EP2331136A4 (en) FRIZZLED-BINDING SUBSTANCES AND ITS USES
EP3444352A3 (en) Production of recombinant vaccine in e. coli by enzymatic conjugation
TN2012000437A1 (en) Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
MX371272B (es) El péptido mots3 derivado de mitocondrias regula el metabolismo y la supervivencia celular.
EA202091242A3 (ru) Новые способы иммунотерапии нескольких видов опухолей, в том числе рака желудочно-кишечного тракта и рака желудка
GT200900126A (es) Novedosos anticuerpos antiproliferacion
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
WO2012068317A3 (en) Methods for producing recombinant proteins
BR112013031084A2 (pt) meios e métodos para imunoterapia celular ativa de câncer usando células tumorais mortas por alta pressão hidrostática e células dendríticas
MX2015017959A (es) Composiciones y metodos para inmunoterapia.
NZ594198A (en) Neil3 peptides and vaccines including the same
GB201019331D0 (en) Methods for the diagnosis and treatment of cancer based on AVL9
GB201017519D0 (en) Vaccines
PE20110775A1 (es) Composicion para dirigirse a las celulas dendriticas
MX2012008657A (es) Peptidos melk modificados y vacunas que contienen los mismos.
MX339746B (es) Vitamina d3 y análogos de la misma para aliviar efectos secundarios asociados con la quimioterapia.
BR112015004349A2 (pt) peptídeos de ube2t e vacinas contendo os mesmos
WO2009062260A8 (en) Therapy for multiple sclerosis
MY178632A (en) Recombinant glycoproteins and uses thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal